Search for: "In re Bartlett"
Results 101 - 120
of 437
Sort by Relevance
|
Sort by Date
24 Jun 2016, 6:31 am
Posted by Anya Kleymenova, University of Chicago, on Friday, June 17, 2016 Tags: Agency costs, Banker bonuses, Compensation regulation, EU, Executive Compensation, Executive turnover,Financial institutions, Financial regulation, Fund managers, Incentives, International governance, Management, Risk-taking, UK SEC Enforcement: Private Equity Broker Registration Posted by Rajib Chanda, Simpson Thacher & Bartlett LLP, on Saturday, June 18, 2016 Tags: Broker-dealers, Fund managers,… [read post]
10 Jun 2016, 9:40 am
And doesn’t this vary depending on what product you’re talking about? [read post]
19 May 2016, 1:33 pm
Second, it evaluated the impact of Bartlett and Mensing on preemption of these “lack of efficacy claims” for a branded prescription drug. [read post]
17 May 2016, 9:15 am
Simpson: We often set forth assumptions and plans and then re-visit quarterly to re-set. [read post]
15 May 2016, 4:10 am
But damn, we’re going to be really unhappy when they get their way. [read post]
2 May 2016, 9:02 pm
Libby Ryan and Jordan D’Addeo are unlikely rabble-rousers. [read post]
22 Apr 2016, 12:51 pm
Utah July 13, 2015); In re DePuy Orthopaedics, Inc. [read post]
22 Apr 2016, 6:06 am
Executive Compensation: 2015 Recap, Developments & Trends Posted by Avrohom Kess & Yafit Cohn, Simpson Thacher & Bartlett LLP, on Friday, April 15, 2016 Tags: Compensation committees, Compensation disclosure, Compensation ratios, Director compensation, Dodd-Frank Act, Equity-based compensation, Executive Compensation, Institutional Investors, Pay for performance, Proxy advisors,Say on frequency, Say on pay, SEC, SEC rulemaking, Securities Regulation Halliburton II:… [read post]
15 Apr 2016, 6:00 am
Kess & Yafit Cohn, Simpson, Thacher & Bartlett LLP, on Tuesday, April 12, 2016 Tags: Charter & bylaws, Compliance and disclosure interpretation, Exchange Act, Proxy disclosure, Proxy materials,Proxy voting, Rule 14a-4, SEC, SEC rulemaking, Securities Regulation, Shareholder proposals, Shareholder voting The Role of the Federal Reserve: Lessons from Financial Crises Posted by William C. [read post]
1 Apr 2016, 3:02 am
According to these re-interpretations, a drug that is unavoidably unsafe should not bring design-based liability; but unavoidability should be proven, not presumed. [read post]
31 Mar 2016, 3:00 am
A short one-two-three punch: Mensing, Bartlett, and Wyeth. [read post]
26 Feb 2016, 3:54 pm
They’re too normal. [read post]
17 Feb 2016, 4:30 am
Stevens held some things preempted and some things not, but good luck figuring that out once you're down to actual cases. [read post]
8 Feb 2016, 1:18 pm
It was proposed to Rabkin by Kathie Bartlett, a member of the MBP board. [read post]
1 Jan 2016, 7:08 am
While this “stop selling” or “never sell” theory has been labeled in various ways (including “fraud on the FDA”) to meet the plaintiff’s particular needs, it seems to us like a re-framing of design defect, albeit without pesky requirements like a feasible alternative design, no liability with adequate (or without inadequate) warnings, or proximate cause. [read post]
31 Dec 2015, 5:12 am
This “never-start selling” claim was also preempted because it was the same as the “stop-selling” claim rejected in Bartlett. [read post]
9 Dec 2015, 6:50 am
Bartlett, 133 S. [read post]
27 Nov 2015, 5:00 am
Thus they pick every preemption nit they can find.That’s what we’re on about today. [read post]
23 Nov 2015, 8:59 am
Bartlett, 133 S. [read post]
21 Nov 2015, 7:50 am
And judges themselves admit they’re different. [read post]
